Analysts focus on three programs in big year for Bristol Myers

April 30, 2026 11:33 AM EDT Pharma As ex­cite­ment grows for Bris­tol My­er­s' pipeline, Kraza­ti con­fir­ma­to­ry study is a mys­tery Max Gelman Senior Editor Wall Street’s ex­pec­ta­tions for Bris­tol My­ers Squibb’s up­com­ing slate of da­ta read­outs are reach­ing a fever pitch. An­a­lysts lobbed ques­tions re­gard­ing at least half a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER